Biotechnology • Pharmaceuticals

EVAST Bio reports no serious adverse events in knee osteoarthritis EV therapy trial

Man in a blue blazer and lanyard stands beside a projected slide on MSC-derived EVs as seated attendees face him
  • EVAST Bio, a spin-off of Chilean company Cells for Cells, presented preliminary Phase I data for its extracellular vesicle therapy in knee osteoarthritis at ExosomesEurope 2026 in Berlin.
  • The open-label, dose-escalation study enrolled 12 patients across three dose cohorts, each receiving a single intra-articular injection of MSC-derived extracellular vesicles.
  • No serious adverse events or dose-limiting toxicities were recorded at any dose level through Month 4, and the primary safety endpoint was met.
  • Preliminary Month 4 data from the low- and medium-dose cohorts showed improvements in four of five KOOS subscales that exceeded published minimum important differences.
  • The company said a randomised, controlled Phase II study in knee osteoarthritis is a key next step.

EVAST Bio, a US-based clinical-stage biotechnology company spun off from Chilean developer Cells for Cells, has reported preliminary Phase I data for its intra-articular extracellular vesicle therapy in patients with knee osteoarthritis (OA). The results were presented at ExosomesEurope 2026 in Berlin in November 2026. The company said the study is the first clinical report on this approach.

Safety results for the extracellular vesicle therapy

The open-label, dose-escalation study enrolled 12 patients with knee OA across three sequential dose cohorts of four patients each. Each patient received a single intra-articular injection of extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) and was followed for four months. The trial is registered as NCT06431152.

The primary endpoints were the incidence of serious adverse events (SAEs) and dose-limiting toxicities (DLTs), graded according to CTCAE v5.0. No SAEs or DLTs were recorded in any patient at any dose level through Month 4, and all 12 patients completed follow-up.

Adverse events were limited to expected Grade 1 local reactions, namely transient post-injection pain, swelling and warmth, which resolved spontaneously in all cases. No systemic events, Grade 2 or higher events, or immunologic reactions were detected. The company said the primary endpoint was met and that intra-articular EV delivery was safe and feasible at the doses studied in an outpatient setting.

“The absence of serious adverse events across all three dose levels, together with the signals we observed in quality of life and physical function, gives us a solid scientific basis to design a properly controlled Phase II study,” said Maroun Khoury, Chief Scientific Officer at EVAST Bio and Cells for Cells.

Exploratory patient-reported outcomes

As pre-specified exploratory endpoints, patient-reported outcomes were collected at baseline and at Months 2 and 4 using three validated instruments: the Knee Injury and Osteoarthritis Outcome Score (KOOS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual Analogue Scale for post-procedural pain.

Preliminary Month 4 results are available for the low- and medium-dose cohorts, both of which showed improvements across multiple subscales. In both cohorts, improvements in four of five KOOS subscales exceeded published minimum important differences. Results from the high-dose cohort are not yet available.

The company noted that these are uncontrolled observations from a single-arm trial without a comparator group. Placebo response in OA trials is well documented, and it said the findings are hypothesis-generating signals rather than evidence of efficacy.

Comparison with earlier cell-based work

The group previously described the preclinical and first-in-human development and the trial protocol in a 2025 paper in the Journal of Nanobiotechnology by Figueroa-Valdés et al. That publication covered GMP manufacturing, product characterisation, in vivo safety and efficacy data, and a proof-of-principle injection in one patient. The team had also run an earlier Phase I dose-escalation trial of umbilical cord-derived MSCs in knee OA, published in Stem Cells Translational Medicine in 2024.

“This is a particularly meaningful result given our previous clinical experience with intra-articular MSC therapy. In our earlier Phase I study, the highest cell dose was associated with injection-related knee swelling in all patients in that cohort, prompting us to discontinue further high-dose enrolment. With EVs, we observed no dose-limiting toxicities or serious adverse events across the three dose levels. Although these are separate studies, the difference in observed tolerability is scientifically compelling and reinforces the potential of a cell-free approach,” said Khoury.

Unmet need and next steps

Knee OA is one of the leading causes of disability in adults worldwide, and no approved disease-modifying OA drug exists; current pharmacological options treat symptoms. MSC-derived EVs carry regulatory RNA, anti-inflammatory proteins and growth factors that may modulate the joint environment. The company said the cell-free product reduces engraftment and immunogenicity concerns compared with cell-based approaches and supports scalable allogeneic manufacturing.

EVAST Bio said knee OA is the first clinical application of its platform, which it intends to extend to other indications and to engineered vesicles for targeted delivery. A randomised, controlled Phase II study of its extracellular vesicle therapy in knee OA is planned as a key next step, alongside work on manufacturing, analytical capabilities and partnerships.

“Extracellular vesicles are attracting considerable attention across biotechnology, but the real opportunity lies in translating their scientific potential into clinically relevant products. At EVast Bio, we are building a therapeutic platform with an ambition that extends well beyond osteoarthritis, from EV-based therapies to engineered vesicles for targeted delivery. Our first clinical data mark an early milestone in that journey, providing a foundation to engage strategic partners, attract investment and advance a broader pipeline of EV therapeutics. In a field defined by its potential, we are taking concrete steps to build clinical evidence,” said Diego Segura, Business Development at Cells for Cells.

Frequently asked questions

What did EVAST Bio’s Phase I knee osteoarthritis trial find?

No serious adverse events or dose-limiting toxicities were recorded in any of the 12 patients at any dose level through Month 4, and the primary safety endpoint was met. Adverse events were limited to transient Grade 1 local reactions.

How was the extracellular vesicle therapy given in the trial?

Each patient received a single intra-articular injection of extracellular vesicles derived from mesenchymal stromal cells and was followed for four months.

Did the trial show the therapy is effective for knee osteoarthritis?

No. Exploratory data from the low- and medium-dose cohorts showed improvements in patient-reported outcomes, but the company said these are uncontrolled, hypothesis-generating signals and not evidence of efficacy.

Where were the EVAST Bio results presented?

The preliminary Phase I data were presented at ExosomesEurope 2026 in Berlin in November 2026.

What are EVAST Bio’s next steps?

The company said a randomised, controlled Phase II study in knee osteoarthritis is a key next step, alongside strengthening manufacturing and analytical capabilities and building strategic partnerships.